If Botox Doesn’t Work as Well as It Used To, Is It Really ‘Resistance’?

First, an important distinction is needed. A subjective sense that the effects have weakened is not enough to diagnose ‘resistance’ to botulinum toxin. Results can also vary depending on the target muscles, injection sites and dose, product-specific units, and the timing of the assessment.

The key point: true neutralizing antibodies are a possible cause, but they are not a common explanation in aesthetic treatment. Before discussing antibody testing, it is more important to compare previous treatments under the same conditions.

What exactly is Botox resistance?

In medical terms, the resistance of concern refers to ‘secondary nonresponse,’ in which neutralizing antibodies block the action of botulinum toxin, reducing or eliminating the response despite repeated appropriate treatment. This is different from simply feeling that the effects did not last as long.

The BOTOX Cosmetic prescribing information states that binding antibodies were detected in 14 of 916 participants (1.5%) in studies of aesthetic indications, but no neutralizing antibodies were detected.[1] A 2023 meta-analysis of approximately 30,000 long-term records also reported that the development of neutralizing antibodies was rare.[2] These figures reflect specific products and study conditions and cannot be applied unchanged to all botulinum toxin products.

What more common factors can make the effects seem shorter-lived?

Dose and ‘units’ are not interchangeable across products

Botulinum toxin units are values determined by each product’s biological assay. Twenty units of one product cannot simply be considered the same amount as 20 units of another. If the brand has changed, check the product name and the actual number of units administered to each area, rather than comparing the numbers alone.[1]

When the target muscles differ, the same expression can look different

Several muscles contribute to glabellar lines. If the previous treatment weakened the center of the glabella but this treatment was injected more conservatively to preserve eyebrow position, more movement may remain, creating the impression that it worked less well. A design intended to preserve natural movement should be distinguished from treatment failure.

The assessment may be too early or too late

It is too early to judge the result based only on changes in facial expression immediately after treatment. Conversely, comparing a memory from several months earlier with photos taken under different lighting and with a different expression can increase the margin of error. It is more accurate to take front-facing and angled photos under the same lighting and with the same expression, then compare them at the assessment time recommended by the clinic.

Can a short-interval ‘touch-up injection’ help?

The risk of antibodies from repeated administration cannot be reduced completely to zero. The prescribing information notes that more frequent intervals or higher doses may increase antibody formation and advises considering the lowest effective dose and the longest possible interval.[1] A 2025 narrative review also identified short intervals, cumulative dose, and early touch-up injections as potential factors, but these are not definitive criteria that apply to every patient.[3]

Therefore, rather than reinjecting the same area a few days later because the effects seem weak, it is better to first compile the product name, lot number, units by treatment area, treatment date, and assessment photos into a single record.

When should true resistance be suspected?

Secondary nonresponse may be suspected if there is little to no response over several treatments, even with different practitioners and appropriate doses, and if someone who initially responded well gradually develops consistent nonresponse. A single short duration of effect or dissatisfaction with one area is not enough.

At that point, reviewing the records should take priority over an additional injection on the same day. After confirming that the target muscles were appropriate, that storage, dilution, and injection were properly managed, and that there are no other neuromuscular disorders or medication-related factors, a specialist evaluation can be considered if necessary.

Frequently asked questions

Will switching products resolve resistance?

Not always. Products differ in protein composition and labeled units, but if neutralizing antibodies are reacting to the core toxin, a simple switch cannot be described as a definitive solution. Other variables that may have made the treatment appear ineffective should be ruled out first.

Will antibodies disappear if I stop Botox?

There is no evidence that stopping treatment for a certain period guarantees the elimination of neutralizing antibodies in everyone. Avoiding unnecessary additional exposure may be meaningful, but the timing of resuming treatment should be determined together with the previous response and the need for treatment.

A practical framework

The first step is not ‘more,’ but ‘comparison under the same conditions.’ Align the previous and current product, units by treatment area, treatment interval, and expression photos taken at around two weeks in a table. If these four fields are blank, there is not yet enough basis to call it resistance—or to increase the dose indiscriminately.